Nishida et al. [34] revealed that loss of TGFBR3, one of the TGF-β pathway molecular, could enhance metastatic abilities in ccRCC through TGF-β-dependent pathway. This evidence concerns the gene TGFBR3 and nonpapillary renal cell carcinoma.